(Doxecitine + doxribtimine) is under clinical development by Zogenix and currently in Phase I for Renal Failure. According to GlobalData, Phase I drugs for Renal Failure have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Doxecitine + doxribtimine)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Doxecitine + doxribtimine) overview

Doxecitine in combination with is doxribtimine under development for the treatment of thymidine kinase 2 deficiency and renal impairment. It is a fixed dose combination. It is a small molecule administered through oral route.

Zogenix overview

Zogenix is a specialty pharmaceutical company that develops and markets therapies for the treatment of patients with rare diseases. The company’s marketed products include Fintepla (fenfluramine) approved in the US, the UK and EU for the treatment of seizures associated with the Dravet syndrome. Its pipeline product candidates include MT1621, intended for the treatment of thymidine kinase 2 deficiency (TK2d); Fintepla for Lennox-Gastaut syndrome (LGS) and other rare epilepsies; and gene therapies for Dravet syndrome and other types of epilepsy. The company operates through its subsidiaries in the US, the UK, Germany, Ireland, Japan, France and Italy. Zogenix is headquartered in Emeryville, California, the US.

For a complete picture of (Doxecitine + doxribtimine)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.